Jeffrey M. Conroy

Publications:

April 30, 2024
Immunologic factors associated with differential response to neoadjuvant chemoimmunotherapy in triple negative breast cancer
March 20, 2024
OX40/OX40 Ligand and its Role in Precision Immune Oncology
March 19, 2024
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
February 5, 2024
Automated Tissue Dissection Solution to Support Comprehensive Genomic and Immune Profiling
September 23, 2023
PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
August 8, 2023
T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
June 12, 2023
LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
June 6, 2023
Sex-specific effects of body composition on tumor microenvironment in non–small cell lung cancer
June 6, 2023
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC)
May 26, 2023
Association of antifolate response signature status and clinical activity of pemetrexed platinum chemotherapy in non-small cell lung cancer - The Piedmont Study
May 8, 2023
RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers
March 21, 2022
Cancer testis antigen burden: pan-cancer distribution and survival implications
November 23, 2024
Comprehensive genomic and immune profiling for the detection of clinically significant tumor biomarkers
November 23, 2024
Analytical validation of OmniSeq® INSIGHT whole transcriptome sequencing assay to facilitate precision oncology through tumoronly testing in solid tumors
November 23, 2024
Analytical validation of OmniSeq® INSIGHT whole exome sequencing assay to facilitate precision oncology through tumor only testing in solid tumors
November 23, 2024
Validation of automated nucleic acid extraction using Covaris® Gen3 extraction methodology on the Assay-Ready Workstation
October 30, 2024
Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer - a case series of divergent results from a large reference laboratory
October 29, 2024
A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
April 7, 2024
Landscape of HIF-1-alpha expression across 24,186 solid tumors using comprehensive immune profiling
April 7, 2024
Landscape of TIGIT and PD-L1 co-expression in solid tumors
February 12, 2024
Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
February 5, 2024
Fully Automated Extraction of High-Quality Total Nucleic Acids from FFPE Specimens using Covaris truXTRAC® FFPE SMART Solutions & Hamilton Robotics
February 5, 2024
Implementation of Laboratory Automation to Support Scaling of Cancer Patients Testing using OmniSeq® INSIGHT Molecular Diagnostic Test
January 30, 2024
LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes
January 13, 2024
Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity
December 11, 2023
Findings of clinically significant variants (Tier IA) with comprehensive genomic profiling in a breast cancer patient cohort
December 11, 2023
Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer
November 17, 2023
Non-V600 BRAF mutated melanomas have immune microenvironments primed for immune checkpoint inhibitor response
November 17, 2023
Genomic stability of prostate cancers with homologous recombination gene alterations
November 17, 2023
Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy
November 17, 2023
Validation of a tumor-informed HLA typing assay to support drug development and clinical decision making
November 17, 2023
LAG-3 expression by RNA next-generation sequencing: Comparison with LAG-3 immunohistochemistry in melanoma
November 17, 2023
A Consensus-Based Machine Learning Framework to Determine Genetically Inferred Ancestry (GIA) from Comprehensive Genomic Profiling (CGP) Sequencing Results
November 4, 2023
Distinct immunotherapy immune response phenotypes in non-small cell lung cancer present with unique genomic alteration profiles
November 3, 2023
Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers
November 3, 2023
Characterization of gene expression signatures of tumor immunogenicity and cellular proliferation from murine cancer models grown in vitro and in vivo
November 3, 2023
Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas
November 3, 2023
Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)
November 3, 2023
Immune microenvironment of primary versus metastatic melanoma of the brain
November 3, 2023
Metastatic triple negative breast cancer has distinct tumor immune landscape
November 1, 2023
Comprehensive Genomic and Immune Profiling of Early-Onset Colorectal Cancer
September 1, 2022
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
March 1, 2022
Checkpoint coexpression landscape in gastroesophageal adenocarcinoma
January 1, 2018
Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors
February 14, 2024
Cancer testis antigen burden (CTAB): a novel biomarker of tumor‑associated antigens in lung cancer

Oncology